Sutapa , Sinha and Veena , Somasundaram and Priya, Srinivas (2013) Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. International journal of cancer, 132 (5). pp. 1201-12. ISSN 1097-0215

Text plumbagin inhibits (Int J Cancer).pdf Restricted to Registered users only Download (1137Kb) | Request a copy

Abstract

Angiogenesis is a hallmark of tumor development and metastatic progression, and anti-angiogenic drugs targeting the VEGF pathway have shown to decrease the disease progression in cancer patients. In this study, we have analyzed the anti-proliferative and anti-angiogenic property of plumbagin in cisplatin sensitive, BRCA2 deficient, PEO-1 and cisplatin resistant, BRCA2 proficient PEO-4 ovarian cancer cells. Both PEO-1 and PEO-4 ovarian cancer cells are sensitive to plumbagin irrespective of BRCA2 status in both normoxia and hypoxia. Importantly, plumbagin treatment effectively inhibits VEGF-A and Glut-1 in PEO-1 and PEO-4 ovarian cancer cells. We have also analyzed the p53 mutant, cisplatin resistant, and BRCA2 proficient OVCAR-5 cells. Plumbagin challenge also restricts the VEGF induced pro-angiogenic signaling in HUVECs and subsequently endothelial cell proliferation. In addition, we observe a significant effect on tumor regression among OVCAR-5 tumor-bearing mice treated with plumbagin, which is associated with significant inhibition of Ki67 and vWF expressions. Plumbagin also significantly reduces CD31 expression in an ear angiogenesis assay. Collectively, our studies indicate that plumbagin, as an anti-cancer agent disrupts growth of ovarian cancer cells through the inhibition of proliferation as well as angiogenesis.

Item Type:	Article
Uncontrolled Keywords:	Plumbagin, Ovarian cancer, Cytotoxicity, Angiogenesis
Subjects:	Cancer Research
Depositing User:	Central Library RGCB
Date Deposited:	06 Feb 2017 05:37
Last Modified:	06 Feb 2017 05:37
URI:	http://rgcb.sciencecentral.in/id/eprint/209

Actions (login required)

View Item